Cargando…
Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials
In previous phase I/II oncology trials for drug combinations, a number of methods have been studied to determine the dose combination for the next cohort. However, there is a risk that trial durations will be unfeasibly long if methods for evaluating safety and efficacy are based on the best overall...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898496/ https://www.ncbi.nlm.nih.gov/pubmed/29696171 http://dx.doi.org/10.1016/j.conctc.2017.05.011 |